News

Antimicrobial Peptides, Skin Infections, and Atopic Dermatitis


 

Tissa R. Hata, MD, and Richard L. Gallo, MD, PhD

The innate immune system evolved more than 2 billion years ago to first recognize pathogens then eradicate them. Several distinct defects in this ancient but rapidly responsive element of human immune defense account for the increased incidence of skin infections in atopics. These defects include abnormalities in the physical barrier of the epidermis, alterations in microbial pattern recognition receptors such as toll receptors and nucleotide binding oligomerization domains, and a diminished capacity to increase the expression of antimicrobial peptides during inflammation. Several antimicrobial peptides are affected including; cathelicidin, HBD-2, and HBD-3, which are lower in lesional skin of atopics compared with other inflammatory skin diseases, and dermcidin, which is decreased in sweat. Other defects in the immune defense barrier of atopics include a relative deficiency in plasmacytoid dendritic cells. In the future, understanding the cause of these defects may allow therapeutic intervention to reduce the incidence of infection in atopic individuals and potentially decrease the severity of this disorder.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

Tacrolimus Comes Out on Top for Treating Atopy
MDedge Dermatology
Long-Term Use of Tacrolimus for AD Flares Found to Reduce Relapse Risk
MDedge Dermatology
Web Use May Be Reason for Eczema Patient's Steroid Fear
MDedge Dermatology
Topical Therapy in Pediatric Atopic Dermatitis
MDedge Dermatology
Pediatric Atopic Dermatitis: The Importance of Food Allergens
MDedge Dermatology
Atopic Dermatitis: Systemic Immunosuppressive Therapy
MDedge Dermatology
Acquired Zinc Deficiency in Full-term Newborns From Decreased Zinc Content in Breast Milk
MDedge Dermatology
Patchy Eczema of Elderly Patients [editorial]
MDedge Dermatology
The Effect of Ceramide-Containing Skin Care Products on Eczema Resolution Duration
MDedge Dermatology
A Single-Center, Double-Blind, Randomized Trial of the Atrophogenic Effects of Fluocinonide Cream 0.1% Versus Clobetasol Propionate Cream 0.05% in Participants With Corticosteroid-Responsive Dermatoses
MDedge Dermatology